Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Kuldeepak Sharma, PhD

President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma
Member of the Healthcare Council

Kuldeepak Sharma, PhD, is a pharmaceutical consultant with twenty years of experience in research, clinical trials, business, patent and product development including: new process & technology development; clinical, project leadership; project planning; project management; patent research; managing research, design and engineering (R,D&E) groups. Dr. Sharma is organized, innovative and entrepreneurial. He is the inventor of ten US patents (four filed, six issued) and has authored about 12 journal papers and 3 book review chapters. Dr. Sharma has developed a unique drug / technology selection model for various drug delivery platforms. Dr. Sharma has successfully transferred the complex drug delivery technology from Japan to USA. A local company has used this model in technology selection and saved about 900K dollars with the help of this model. (This is me - Update Profile)


Employment History
2003 - present President/Pharmaceutical Consultant
Dr. Kuldeepak Sharma

GLG Study Groups with Kuldeepak Sharma, PhD(?)

GLG NewsSM Analyses by Kuldeepak Sharma, PhD(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Lower safer dose of Soma approved by FDA | 09-24-2007
Analysis of: FDA approves SOMA 250 mg | www.pipelinereview.com
Author: Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

As a pharmaceutical consultant working in pain management area, I think lower dose will offer similar efficacy as Soma 350 mg but with a more favorable tolerability profile. Last week, Last week, The Food and Drug Administration (FDA) have approved 250 mg (lower dose) of Soma (carisoprodol) for treatment...

Good News: First Generic Versions of Coreg is Approved | 09-10-2007
Author: Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

 Food and Drug Administration (FDA) has approved the first generic versions of Coreg (carvedilol).  It is good news for patients. Coreg is a widely used medication that is FDA-approved to treat high blood pressure, mild to severe chronic heart failure and left ventricular dysfunction following...

Sharpe Rise of Opioid Drugs Abuse in United State | 08-30-2007
Analysis of: Painkiller Widely Abused in South | www.washingtonpost.com
Author: Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

This article is sad but consistent with overall increase use / abuse of opioids pain killers such as morphine, oxycodone, and hydrocodone. As a pharmacist & pharmaceutical consultant I think these are main reasons for alarming increase of opioids drugs use in America: The population is getting older....

Major Step for Personalized Medicine: Warfarin Sensitivity DNA Test Required By FDA | 08-20-2007
Analysis of: PERSONAL DOSE | online.wsj.com
Author: Kuldeepak Sharma, PhD, President/Pharmaceutical Consultant, Dr. Kuldeepak Sharma

The FDA has announced changes in the Warfarin label, recommending that a lower initial Warfarin dose should be considered for patients with certain genetic variations. Warfarin (Coumadin) is a commonly prescribed blood thinner with an exceptionally narrow safe-dosage range that varies dramatically from...

View All GLG News SM Analyses by Kuldeepak Sharma, PhD

GLG InstituteSM Seminars with Kuldeepak Sharma, PhD(?)

 

Recent Seminars

GLGi: Drug Delivery Technologies
San Francisco, 07-31-2007

Request a project with Kuldeepak Sharma, PhD









Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics